NASDAQ · Health care

Onconetix, Inc. (ONCO)

Onconetix, Inc. brought in $645.8K of revenue over the twelve months to June 30, 2026, down 51.3% from a year earlier. It posted a net loss of $10.2M. At June 30, 2026 it held $5.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Price

$1.03

+13.08% on the day · September 25, 2026

52-week range $0.59 to $209.50

Market cap

$4.1M

Revenue (last 12 months)

$645.8K

-51.3% year on year

Net margin

-1,578.8%

What Onconetix, Inc. does

Onconetix, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ONCO.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$815.4K	-$17.9M	-$14M	-$16.56	n/a
2024	$2.5M	-$56.5M	-$58.7M	-$1,823.39	-$10.5M
2023	$58.5K	-$36M	-$37.4M	-$7,433.82	-$13.6M
2022	n/a	-$13.5M	-$13.4M	-$3,733.88	-$8.7M
2022	n/a	-$3.4M	-$3.4M	-$4,276.99	-$2M

Next report expected around October 29, 2026.

Estimated from its filing rhythm: about 77 days after its last report of August 13, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where ONCO ranks in Health care

Revenue$815.4K

#579 of 646 in Health care · Bottom 10%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

Onconetix, Inc. declared $1.23 per share in fiscal 2022.

Fiscal year	Per share	Paid out	Of profit
2022	$1.23	n/a	n/a

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Onconetix, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 17, 2026
Preliminary proxy statement PRE 14A
September 14, 2026
Additional proxy material DEFA14A
September 14, 2026
Material agreement 8-K
September 14, 2026
Form 425 filing 425
September 8, 2026
Securities offering prospectus 424B3
September 3, 2026
Form 425 filing 425
August 31, 2026
IPO registration (amended) S-1/A
August 13, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue fell 84% to $17.1K versus the same quarter last year; diluted EPS -$1.28 versus -$237.91.
August 12, 2026
IPO registration S-1
August 6, 2026
Form 425 filing 425

Recent insider filings (Forms 3, 4 and 144): 10, the latest on April 22, 2026. Insider transactions on SEC

Who owns ONCO

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Keystone Capital Partners, LLC13G, passive with 2 related filers	6.1%	223,717	July 27, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ONCO

What does Onconetix, Inc. do?

Onconetix, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ONCO.

Is Onconetix, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $10.2M on revenue of $645.8K.

How much revenue does Onconetix, Inc. make?

Over the twelve months to June 30, 2026 Onconetix, Inc. reported revenue of $645.8K. That is 51.3% less than a year earlier.

When did Onconetix, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the preliminary proxy statement from September 17, 2026.

Similar companies

Compare ONCO with

Compare ONCO with any company

Follow ONCO

Get an email when Onconetix, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ONCO: get an email when it files

Where the numbers come from

Financial figures are the values Onconetix, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.